Federal Register #E00520260

Licensing Opportunity: Novel Pan Anti-HLA Monoclonal Antibodies for Cancer Immunotherapy

This opportunity from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), offers a government-owned invention for licensing and collaborative research. - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs and Vendors: - No commercial OEMs or vendors are named; the technology is developed by NIAID/NIH - Products/Services Requested: - Licensing and collaborative research for novel pan anti-HLA monoclonal antibodies (3C10 and 15B1) - Antibodies are designed to block LILR inhibitory receptors and activate anti-tumor immunity - Intended for use in cancer immunotherapy and treatment of chronic infections (e.g., TB, HIV, hepatitis B or C) - Intellectual property reference: HHS Reference No. E00520260, Provisional Patent Application No. 64/053,946 - Unique or Notable Requirements: - Technology is in the pre-clinical stage - Opportunity is for licensing and collaborative research, not for procurement of finished goods - Antibodies demonstrate stronger binding to MHCI and activation of human NK and T cells, supporting next-generation checkpoint therapies

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), announces the availability of a government-owned invention for licensing. The invention involves novel pan anti-HLA monoclonal antibodies designed to block LILR inhibitory receptors and activate anti-tumor immunity, potentially improving cancer immunotherapy. The technology is in the pre-clinical stage and aims to support the development of next-generation checkpoint therapies. Licensing and collaborative research opportunities are available to facilitate commercialization and further development.

View original listing